CYTX - サイトリ・セラピュ―ティクス （Cytori Therapeutics Inc.） サイトリ・セラピュ―ティクスCYTXのチャート
CYTXの企業情報
| symbol | CYTx |
|---|---|
| 会社名 | Cytori Therapeutics Inc （サイトリ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 サイトリ・セラピューティクス(Cytori Therapeutics Inc.)は自体皮下脂肪組織由来の細胞群(ADRC)に基づく細胞療法を開発し、心血管疾患の治療及び軟部組織欠損の修復を行う。同社は心血管疾患の治療用の先端治療アプリケーション等の臨床パイプラインを提供する。同社の製品は「Celbrush」、「Puregraft」及び「Cytori LipoBank」を含む。「Celbrush」は10ミリリットルと3ミリリットルのサイズで対応するサイズのソフトジェクトシリンジと一緒に使用される。「Puregraft」システムは自体脂肪移植と美的体形矯正のために設計されたシステムである。「Puregraft」システムは50～250ミリリットルの組織を処理する250ミリリットル、および200～850ミリリットルの組織を処理する850ミリリットルの2種のサイズで使用される。「Cytori LipoBank」はヒト細胞組織操作規範（GTP）準拠の凍結保存システムであり、単一の脂肪吸引後の生存脂肪組織の長期貯蔵機能を提供する。 サイトリ・セラピュ―ティクスは米国で細胞療法を開発、研究。強皮症、膝関節変形性関節炎、放射線深部熱傷のための幹細胞を使った療法(「サイトリ・セル・セラピ―」)の治験を行う。「サイトリ・セル・セラピ―」の一環として、幹細胞の採取源である脂肪組織由来再生細胞の抽出装置(遠心分離器)「セル―ション」を商品化中。 Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA. |
| 本社所在地 | 3020 Callan Road San Diego CA 92121 USA |
| 代表者氏名 | Richard James Hawkins リチャードジェームスホーキンス |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-458-0900 |
| 設立年月日 | 35551 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 80人 |
| url | www.cytori.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.26700 |
| 終値（lastsale） | 0.3903 |
| 時価総額（marketcap） | 3008406.6402 |
| 時価総額 | 時価総額（百万ドル） 4.34275 |
| 売上高 | 売上高（百万ドル） 6.50800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 15.09975 |
| 当期純利益 | 当期純利益（百万ドル） -21.13900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytori Therapeutics Inc revenues increased 3% to $3.2M. Net loss decreased 41% to $8.1M. Revenues reflect Government contracts and other increase of 17% to $1.8M. Lower net loss reflects Purchased R&D Written Off decrease from $1.7M (expense) to $0K Interest expense decrease of 23% to $867K (expense) Interest Income increase of 6% to $19K (income). |
CYTXのテクニカル分析
CYTXのニュース
Cytori Therapeutics CFO Gary Titus Resigns 2019/07/05 14:21:00 The Wall Street Journal
Cytori Therapeutics Inc. finance chief and secretary Gary Titus has resigned from his positions, the company said Friday.
Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug 2019/07/05 13:39:51 Benzinga
Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX ), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday. What Happened Cytori said in an filing with the SEC that CFO Gary Titus notified the company of his intention to resign from his position effective immediately; Cytori said he will continue with the company as an adviser. The company said its board has approved the appointment of Alan Lins as Titus' successor as vice president of finance and controller. The company … Full story available on Benzinga.com
Cytori Therapeutics Inc (NASDAQ:CYTX) - Cytori Therapeutics shares are trading higher after the company announced it would divest certain cell therapy assets to Seijiro Shirahama of Tokyo for $3 million in non-dilutive funding for the company. 2019/04/23 09:27:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
Cytori Therapeutics Inc.'s (CYTX) CEO Marc Hedrick on Q4 2018 Results - Earnings Call Transcript 2019/04/01 16:46:20 Seeking Alpha
Cytori Therapeutics CFO Gary Titus Resigns 2019/07/05 14:21:00 The Wall Street Journal
Cytori Therapeutics Inc. finance chief and secretary Gary Titus has resigned from his positions, the company said Friday.
Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug 2019/07/05 13:39:51 Benzinga
Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX ), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday. What Happened Cytori said in an filing with the SEC that CFO Gary Titus notified the company of his intention to resign from his position effective immediately; Cytori said he will continue with the company as an adviser. The company said its board has approved the appointment of Alan Lins as Titus' successor as vice president of finance and controller. The company … Full story available on Benzinga.com
Cytori Therapeutics Inc (NASDAQ:CYTX) - Cytori Therapeutics shares are trading higher after the company announced it would divest certain cell therapy assets to Seijiro Shirahama of Tokyo for $3 million in non-dilutive funding for the company. 2019/04/23 09:27:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
Cytori Therapeutics Inc.'s (CYTX) CEO Marc Hedrick on Q4 2018 Results - Earnings Call Transcript 2019/04/01 16:46:20 Seeking Alpha
Cytori Therapeutics CFO Gary Titus Resigns 2019/07/05 14:21:00 The Wall Street Journal
Cytori Therapeutics Inc. finance chief and secretary Gary Titus has resigned from his positions, the company said Friday.
Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug 2019/07/05 13:39:51 Benzinga
Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX ), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday. What Happened Cytori said in an filing with the SEC that CFO Gary Titus notified the company of his intention to resign from his position effective immediately; Cytori said he will continue with the company as an adviser. The company said its board has approved the appointment of Alan Lins as Titus' successor as vice president of finance and controller. The company … Full story available on Benzinga.com
Cytori Therapeutics Inc (NASDAQ:CYTX) - Cytori Therapeutics shares are trading higher after the company announced it would divest certain cell therapy assets to Seijiro Shirahama of Tokyo for $3 million in non-dilutive funding for the company. 2019/04/23 09:27:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …